windtreetx.com Open in urlscan Pro
2a06:98c1:3120::3  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * COMPANY
   * COMPANY OVERVIEW
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * CONTACT US
   * DIVERSITY, INCLUSION AND INNOVATION
 * PIPELINE AND TECHNOLOGY
   * Pipeline and Therapeutic overview
   * Istaroxime
   * SERCA2a Activators
   * Lucinactant (KL4 surfactant)
   * AEROSURF®
   * Rostafuroxin
   * Expanded Access Policy
 * BUSINESS DEVELOPMENT
 * INVESTORS
   * Welcome
   * Press Releases
   * EVENTS
   * Corporate Presentation
   * Corporate Governance
   * FILINGS
     * SEC FILINGS
     * OWNERSHIP
   * STOCK INFORMATION
     * STOCK QUOTE & CHART
     * HISTORIC PRICE LOOKUP
   * FINANCIAL FUNDAMENTALS
   * FINANCIAL INFORMATION
     * IR SNAPSHOT
     * ANNUAL REPORTS
     * ANALYST COVERAGE
   * Investor Alerts
 * CONTACT US

Select Page
 * COMPANY
   * COMPANY OVERVIEW
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * CONTACT US
   * DIVERSITY, INCLUSION AND INNOVATION
 * PIPELINE AND TECHNOLOGY
   * Pipeline and Therapeutic overview
   * Istaroxime
   * SERCA2a Activators
   * Lucinactant (KL4 surfactant)
   * AEROSURF®
   * Rostafuroxin
   * Expanded Access Policy
 * BUSINESS DEVELOPMENT
 * INVESTORS
   * Welcome
   * Press Releases
   * EVENTS
   * Corporate Presentation
   * Corporate Governance
   * FILINGS
     * SEC FILINGS
     * OWNERSHIP
   * STOCK INFORMATION
     * STOCK QUOTE & CHART
     * HISTORIC PRICE LOOKUP
   * FINANCIAL FUNDAMENTALS
   * FINANCIAL INFORMATION
     * IR SNAPSHOT
     * ANNUAL REPORTS
     * ANALYST COVERAGE
   * Investor Alerts
 * CONTACT US

   
 *  
   
   






WELCOME TO WINDTREE THERAPEUTICS


DELIVERING INNOVATIVE TREATMENT AND HOPE FOR PATIENTS IN THEIR MOMENTS OF CRISIS

We are a clinical-stage, biopharmaceutical and medical device company focused on
the development of novel therapeutics intended to address significant unmet
medical needs in important acute care markets. Our development programs are
primarily focused on the treatment of acute cardiovascular and acute pulmonary
diseases in areas with high unmet needs; 2 programs have Fast-Track designation.
We are developing istaroxime as a first-in-class treatment for acute heart
failure and early cardiogenic shock. We are evaluating lucinactant (KL4
surfactant) in adults with COVID-19 associated lung injury who are intubated and
on mechanical ventilation in an intensive care unit. We are also developing
AEROSURF®, a drug-device combination to aerosolize lucinactant, in partnership
with our licensee in Asia, as a non-invasive treatment for premature infants
with respiratory distress syndrome (RDS).

 

Our lead acute cardiovascular product candidate, istaroxime, is a
first-in-class, dual-acting agent being developed to improve cardiac function in
patients with acute heart failure, or AHF, with a potentially differentiated
safety profile from existing treatments. Lucinactant is a synthetic KL4
surfactant, structurally similar to human pulmonary surfactant. In COVID-19
patients, we believe lucinactant may mitigate the surfactant abnormalities that
can occur in severe lung injury potentially limiting lung damage, improving
oxygenation and lung compliance, and reducing time on mechanical ventilation or
days in the intensive care unit. AEROSURF® is drug-device combination that
incorporates lucinactant and a proprietary aerosol delivery system to
non-invasively deliver surfactant to premature infants suffering from RDS, a
complication resulting from inadequate surfactant production. In all we do, we
are driven by compassion and the aspiration to help patients and their families
navigate unexpected medical crises to provide hope for a life less impacted by
disease.

Learn More


Istaroxime is a first–in–class dual mechanism therapy designed to
improve cardiac function by increasing both systolic contractions of the
heart as well as diastolic relaxation through SERCA2a activation and
Na+/K+ ATPase inhibition.

Learn More


Lucinactant (KL4 surfactant) is structurally similar to human pulmonary
surfactant but is synthetic. We are studying lucinactant dosed as a liquid
instillate in a small Phase 2 pilot study to assess its ability to impact key
respiratory parameters in the treatment of lung injury and acute respiratory
distress syndrome, or ARDS, COVID-19 infections

Learn More

AEROSURF® is drug-device combination that incorporates lucinactant to treat
premature infants suffering from RDS, a complication with preterm births due to
the infant’s lungs lacking endogenous surfactant. AEROSURF® allows the
healthcare professional to non-invasively deliver surfactant using Windtree’s
proprietary aerosol delivery system (ADS) in order to avoid common complications
associated with invasive administration, intubation and ventilation.

Learn More



“Our mission is clear – to support patients in crisis situations by arming the
healthcare providers with therapies that significantly improve upon current
standards of care. We are developing important critical care innovations that
have the potential to address some of the most significant unmet medical needs
and will strive to deliver them responsibly with unrelenting attention to
quality and access to care.”


— CRAIG FRASER

© Copyright 2022 Windtree Therapeutics, Inc.